On the US business previously guidance 6.5m EBITDAF now revised to 1.3m for FY18. Question is how much will be offset by overperformance in other businesses.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025